Skip to content
Head to head

Maravai LifeSciences vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: MRVI · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

MRVI +109.0%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
MRVIVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price6.98515.02
Change today-2.92%-1.08%
1-year return+104.1%+22.0%
Market cap$1.04B$130.58B
52-week range2.80 – 9.42412.27 – 568.67
Valuation
P/E (TTM)-15.8633.14
P/E percentile, own 5-yr range0th99th
P/B5.326.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.9015.32
Net profit (TTM)$-134.33M$3.88B
Revenue (TTM)$213.00M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+10.1%+11.8%
Gross margin39.1%85.5%
Operating margin-25.6%33.1%
Net margin-30.8%30.7%
Free cash flow (TTM)$-13.27M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership103.1%96.8%
Insider activity (12mo)27 buy / 23 sell28 buy / 22 sell
Short interest (% of float)9.4%1.9%
Analyst consensus100% buy (4)95% buy / 5% hold (21)
Analyst price target$10 (+42%)$624 (+21%)
StockVane view
StockVane Quant RatingC (97)C (68)
Company
Employees4356,400
Founded20141989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.